

SECTION I
AMENDMENTS

IN THE CLAIMS:

Please cancel claims 2, 3, 22, 28, and 31-35, without prejudice.

Please amend claims 1, 10, 20, and 24-27, as set forth below.

Complete Listing of the Claims

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

1. (Currently Amended) A diagnostic conjugate for tumor imaging having the structure: transmembrane module (TPU) ~~[[-]]~~ coupled via a spacer to an address module (AS) ~~[[-]]~~ coupled via a spacer to a signalling module (SM); wherein
 - the transmembrane module is a cell-penetrating human transmembrane peptide comprising the amino acid sequence KMTRQTWWHRIKHKC (SEQ ID NO: 2), MTROTFWHRIKHKC (SEQ ID NO: 3) or KHKIRHWFTORTMC (SEQ ID NO: 4) transport peptide capable of penetrating the plasma membrane;
 - the address module is a peptide nucleic acid (PNA) antisense to and hybridizing with a mRNA selected from a group consisting of c-myc-, c-ras-, hem-, sst1, or sst2-mRNA; and
 - the signalling module is a compound trapping Gadolinium.
- 2.-7. (Cancelled)
8. (Previously Presented) The diagnostic conjugate of claim 1, wherein the peptide nucleic acid (PNA) comprises the sequence H₂N-ATGCCCTCAACGTTAGCTT-COOH (SEQ ID NO: 5).
9. (Cancelled)
10. (Currently Amended) The diagnostic conjugate of claim 1, wherein the transmembrane module (TPU) is coupled to the address module (AS) via a covalently cleavable spacer I and/or the address module (AS) is coupled to ~~the signalling module (SM)~~ or a compound trapping the signalling module (SM) via a covalently non-cleavable spacer II.

11. (Original) The diagnostic conjugate of claim 10, wherein spacer I comprises a cleavable disulfide bridge.
12. (Original) The diagnostic conjugate of claim 10, wherein spacer I and/or spacer II comprises polylysine or polyglycine.
13. (Previously presented) The diagnostic conjugate of claim 12, wherein spacer II carries an FITC-label.
14. (Previously presented) The diagnostic conjugate of claim 1 having the following structure: transmembrane module (TPU) - spacer I comprising a cleavable disulfide bridge - address module (AS) - spacer II - signalling module (SM) or compound trapping the signalling module (SM).
15. (Previously presented) A diagnostic composition containing a diagnostic conjugate of claim 1.
- 16.-18. (Cancelled)
19. (Previously presented) A diagnostic composition containing a diagnostic conjugate of claim 14.
20. (Currently Amended) A diagnostic conjugate for tumor imaging having the structure: transmembrane module (TPU) ~~[[-]]~~ coupled via a cleavable spacer I to an address module (AS) ~~[[-]]~~ coupled via a spacer II to a signalling module (SM), wherein
 - the transmembrane module (TPU) is a cell-penetrating human transmembrane peptide of the amino acid sequence KMTROTWWHRIKHKC (SEQ ID NO: 2), MTRQTFWHRIKHKC (SEQ ID NO: 3) or KHKIRHWFTQRTMC (SEQ ID NO: 4) transport peptide capable of penetrating the plasma membrane selected from the group consisting of penetratin and transportan;
 - the address module (AS) is a peptide nucleic acid (PNA) antisense to and hybridizing with a mRNA of a gene selected from the group consisting of c-myc-, c-ras-, henn-1, sst1 or sst2; and
 - the signalling module (SM) is ~~a compound~~ diethylenetriaminetriaminopentaacetic acid (DTPA) trapping Gadolinium.

- 21.-22. (Cancelled)
23. (Previously Presented) The diagnostic conjugate of claim 20, wherein the peptide nucleic acid (PNA) comprises the sequence H₂N-ATGCCCTCAACGTTAGCTT-COOH (SEQ ID NO: 5).
24. (Currently Amended) The diagnostic conjugate of claim 20, wherein ~~the transmembrane module (TPU) is coupled to the~~ address module (AS) via a covalently cleavable spacer I and/or the address module (AS) is coupled to the ~~signalling module (SM) or a~~ compound trapping the signalling module (SM) via a covalently non-cleavable spacer II.
25. (Currently Amended) The diagnostic conjugate of claim ~~24~~20, wherein spacer I comprises a cleavable disulfide bridge.
26. (Currently Amended) The diagnostic conjugate of claim ~~24~~20, wherein spacer I and/or spacer II comprises polylysine or polyglycine.
27. (Currently Amended) The diagnostic conjugate of claim ~~25~~24, wherein spacer II carries an FITC-label.
28. (Cancelled)
29. (Previously Presented) A diagnostic composition containing a diagnostic conjugate of claim 20 and pharmaceutically acceptable carrier.
30. (Previously Presented) The diagnostic conjugate of claim 1, wherein the compound trapping Gadolinium is diethylenetriaminetriaminepentaacetic acid (DTPA).
- 31.-35. (Cancelled)

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK